Aug 14, 2026 04:15PM
Jul 16, 2026 07:31AM
Jul 16, 2026 07:30AM
Jun 30, 2026 07:31AM
Jun 30, 2026 07:30AM
May 15, 2026 04:05PM
May 15, 2026 04:05PM Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
May 8, 2026 07:30AM
May 8, 2026 07:30AM
Apr 23, 2026 07:30AM
Apr 23, 2026 07:30AM
Apr 8, 2026 07:30AM
Apr 8, 2026 07:30AM
Mar 12, 2026 04:15PM Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
Jan 22, 2026 07:45AM
Jan 22, 2026 07:45AM
Jan 8, 2026 07:31AM
Jan 8, 2026 07:30AM
Nov 26, 2025 07:48AM
Nov 24, 2025 07:31AM
Nov 24, 2025 07:30AM Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
Nov 6, 2025 07:30AM
Nov 6, 2025 07:30AM
Oct 30, 2025 04:15PM
Aug 14, 2025 04:15PM
Jul 8, 2025 07:31AM
Jul 8, 2025 07:30AM
Jun 30, 2025 07:30AM Plus Therapeutics (PSTV) Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ
Jun 30, 2025 07:30AM
Jun 26, 2025 07:31AM
Jun 26, 2025 07:30AM
Jun 25, 2025 07:30AM
Jun 25, 2025 07:30AM
May 30, 2025 04:15PM
May 14, 2025 07:31AM Plus Therapeutics (PSTV) Says REYOBIQ Showed Clinical Benefit and Safety in the ReSPECT-LM Trial
May 14, 2025 07:30AM
Apr 15, 2025 07:30AM
Apr 15, 2025 07:30AM
Mar 27, 2025 04:05PM
Mar 20, 2025 07:30AM
Mar 20, 2025 07:30AM
Mar 7, 2025 07:30AM Plus Therapeutics (PSTV) Announces Publication Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Mar 7, 2025 07:30AM
Mar 6, 2025 07:32AM
Mar 6, 2025 07:30AM
Feb 26, 2025 07:30AM
Feb 26, 2025 07:30AM
Feb 24, 2025 07:31AM
Feb 24, 2025 07:30AM Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Feb 20, 2025 07:30AM

329,910 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All